Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.42 |
| ▸ | FABP7 | O15540 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16424441 | 0.96 | KMT2A (0.44) | KMT2AFABP5FABP7EPHX2TSHR | |
| SCHEMBL30555288 | 0.80 | TSHR (0.50) | KMT2AFABP5FABP7EPHX2TSHR | |
| SCHEMBL30824716 | 0.80 | TSHR (0.50) | KMT2AFABP5FABP7EPHX2TSHR | |
| SCHEMBL8222797 | 0.80 | TSHR (0.50) | KMT2AFABP5FABP7EPHX2TSHR | |
| SCHEMBL1202245 | 0.79 | KMT2A (0.48) | KMT2AFABP5FABP7EPHX2TSHR | |
| SCHEMBL30276687 | 0.79 | TSHR (0.52) | KMT2AFABP5FABP7EPHX2TSHR | |
| SCHEMBL30253490 | 0.79 | KMT2A (0.48) | KMT2AFABP5FABP7EPHX2TSHR | |
| SCHEMBL31220527 | 0.79 | TSHR (0.52) | KMT2AFABP5FABP7EPHX2TSHR | |
| SCHEMBL29617524 | 0.79 | KMT2A (0.48) | KMT2AFABP5FABP7EPHX2TSHR | |
| SCHEMBL711979 | 0.79 | TSHR (0.52) | KMT2AFABP5FABP7EPHX2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4592275-A2 | HYDRAZINYL-PYRROLO COMPOUNDS AND METHODS FOR PRODUCING A CONJUGATE | Redwood Bioscience, Inc. (US) | 2025-07-30 | — | — | EP | disclosed |
| US-20250223302-A1 | CAMPTOTHECINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | R.P. SCHERER TECHNOLOGIES, LLC | 2025-07-10 | — | — | US | disclosed |
| EP-3074010-B1 | HYDRAZINYL-PYRROLO COMPOUNDS AND METHODS FOR PRODUCING A CONJUGATE | REDWOOD BIOSCIENCE INC (US) | 2025-05-14 | — | — | EP | disclosed |
| US-12215080-B2 | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate | REDWOOD BIOSCIENCE, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-12187745-B2 | Camptothecine antibody-drug conjugates and methods of use thereof | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2025-01-07 | — | — | US | disclosed |
| EP-4301415-A1 | BRANCHED LINKERS FOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | R.P. Scherer Technologies, LLC (US) | 2024-01-10 | — | — | EP | disclosed |
| CN-116847844-A | Camptothecine antibody-drug conjugates and methods of use thereof | R.P.谢勒技术有限责任公司 | 2023-10-03 | — | — | CN | disclosed |
| US-20230277676-A1 | CAMPTOTHECINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | ARES CAPITAL CORPORATION, AS COLLATERAL AGENT | 2023-09-07 | — | — | US | disclosed |
| US-11696904-B2 | Prodrug for therapeutic applications | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-11 | — | — | US | disclosed |
| US-11564989-B2 | Camptothecine antibody-drug conjugates and methods of use thereof | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2023-01-31 | — | — | US | disclosed |
| US-11180451-B2 | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate | REDWOOD BIOSCIENCE, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20200317610-A1 | Hydrazinyl-Pyrrolo Compounds and Methods for Producing a Conjugate | ARES CAPITAL CORPORATION, AS COLLATERAL AGENT | 2020-10-08 | — | — | US | disclosed |
| US-10604483-B2 | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate | REDWOOD BIOSCIENCE, INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-10464894-B2 | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate | REDWOOD BIOSCIENCES, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20170049907-A1 | HYDRAZINYL-PYRROLO COMPOUNDS AND METHODS FOR PRODUCING A CONJUGATE | CATALENT PHARMA SOLUTIONS, LLC | 2017-02-23 | — | — | US | disclosed |
| US-9493413-B2 | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate | REDWOOD BIOSCIENCE, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| CN-103415540-B | The manufacture method of photosensitive composite, cured article and active ray cured article | SANYO CHEMICAL INDUSTRIES, LTD. (JP) | 2016-03-23 | — | — | CN | disclosed |
| US-20150157736-A1 | HYDRAZINYL-PYRROLO COMPOUNDS AND METHODS FOR PRODUCING A CONJUGATE | R.P. SCHERER TECHNOLOGIES, LLC | 2015-06-11 | — | — | US | disclosed |
| US-20140045966-A1 | PHOTOSENSITIVE COMPOSITION. CURED ARTICLE, AND METHOD FOR PRODUCING ACTINICALLY CURED ARTICLE | SANYO CHEMICAL INDUSTRIES, LTD. (JP) | 2014-02-13 | — | — | US | disclosed |
| CN-103415540-A | Photosensitive composition, cured article, and method for producing actinically cured article | SANYO CHEMICAL IND LTD | 2013-11-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150157736-A1 | HYDRAZINYL-PYRROLO COMPOUNDS AND METHODS FOR PRODUCING A CONJUGATE | DNPEP, QPCT, PDS5A | KMT2A 1630/4885FABP5 2313/4885FABP7 2484/4885 |
| US-20170049907-A1 | HYDRAZINYL-PYRROLO COMPOUNDS AND METHODS FOR PRODUCING A CONJUGATE | DNPEP, QPCT, PDS5A | KMT2A 1630/4885FABP5 2313/4885FABP7 2484/4885 |
| US-20230277676-A1 | CAMPTOTHECINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | DCTD, ADCY8, ADCY3 | KMT2A 1187/4885FABP5 4322/4885FABP7 4234/4885 |
| US-12187745-B2 | Camptothecine antibody-drug conjugates and methods of use thereof | DCTD, ADCY8, ADCY3 | KMT2A 1187/4885FABP5 4322/4885FABP7 4234/4885 |
| US-12215080-B2 | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate | DNPEP, QPCT, PDS5A | KMT2A 1630/4885FABP5 2313/4885FABP7 2484/4885 |
| US-11696904-B2 | Prodrug for therapeutic applications | S1PR2, S1PR5, S1PR4 | KMT2A 1443/4885FABP5 2450/4885FABP7 986/4885 |
| US-20250223302-A1 | CAMPTOTHECINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | DCTD, ADCY8, ADCY3 | KMT2A 1187/4885FABP5 4322/4885FABP7 4234/4885 |
| US-11180451-B2 | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate | DNPEP, QPCT, PDS5A | KMT2A 1630/4885FABP5 2313/4885FABP7 2484/4885 |
| US-10464894-B2 | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate | DNPEP, QPCT, PDS5A | KMT2A 1630/4885FABP5 2313/4885FABP7 2484/4885 |
| US-10604483-B2 | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate | DNPEP, QPCT, PDS5A | KMT2A 1630/4885FABP5 2313/4885FABP7 2484/4885 |
| US-20200317610-A1 | Hydrazinyl-Pyrrolo Compounds and Methods for Producing a Conjugate | DNPEP, QPCT, PDS5A | KMT2A 1630/4885FABP5 2313/4885FABP7 2484/4885 |
| US-11564989-B2 | Camptothecine antibody-drug conjugates and methods of use thereof | DCTD, ADCY8, ADCY3 | KMT2A 1187/4885FABP5 4322/4885FABP7 4234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.